VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Pathogen Page
Plasmodium spp.

Table of Contents

  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. ABRA
    2. AMA-1 from P. berghei
    3. AMA-1 from P. chabaudi
    4. AMA1 from P. falciparum 3D7
    5. AMA1 from P. knowlesi
    6. cjaA
    7. CS from P. berghei str. ANKA
    8. CS from P. falciparum
    9. CS from P. vivax
    10. CS from P. yoelii
    11. CSP from P. falciparum
    12. CSP from P. knowlesi
    13. eba-175
    14. Exported protein 1 from Plasmodium falciparum
    15. FabB/FabF
    16. FCR3S1.2-var1
    17. GLURP
    18. HEP17
    19. HSP60 from P. yoelii
    20. Hsp90
    21. Kbeta
    22. LSA-1 from Plasmodium falciparum
    23. LSA-3
    24. MSP-1 from P. falciparum
    25. msp-8
    26. MSP1 from P. berghei
    27. MSP1 from P. knowlesi
    28. MSP1 from P. yoelii str. 17XNL
    29. MSP1 from P.vivax
    30. MSP2
    31. msp3
    32. MSP4
    33. MSP4/5
    34. P36p
    35. p52
    36. pfCelTOS
    37. Pfen
    38. PfP0
    39. Pfs230
    40. Pfs25 from P. falciparum 3D7
    41. Pfs48/45
    42. PvCelTOS
    43. PvDBPII
    44. Pvs25
    45. PY01338
    46. Py36
    47. Py52
    48. RESA
    49. RH5
    50. SERA
    51. SERA-5
    52. SSP2
    53. SSP2 from P. knowlesi
    54. SSP2 from Plasmodium falciparum
    55. STARP
    56. TRAP from P. falciparum
    57. UIS3
    58. UIS4
  3. Vaccine Information
    1. Ad-MVA PvCelTOS
    2. Ad-protein PvCelTOS
    3. Ad-VLPs PvCelTOS
    4. AMA 49-CPE
    5. AMA1-C1Alhydrogel
    6. AMA1-C1Alhydrogel + CPG 7909
    7. BDES-PfCSP (baculovirus dual expression system)
    8. ChAd63 -PvTRAP
    9. ChAd63 MVA PvDBP
    10. ChAd63-MVA AMA1
    11. ChAd63-MVA ME-TRAP
    12. ChAd63-MVA MSP1
    13. ChAd63-MVA RH5
    14. ChAd63/MVA Pfs25-IMX313
    15. FMP012 with AS01B adjuvant system
    16. FMP1/AS02A
    17. MSP3-CRM-Vac4All/ Alhydrogel®
    18. MSP3-LSP with aluminium hydroxide
    19. MVA-PvTRAP
    20. NILV-Py CSP
    21. NYVAC-CSP (malaria)
    22. NYVAC-Pf7
    23. P. berghei CS Protein Subunit Vaccine
    24. P. berghei DNA vaccine CSP-3p28
    25. P. berghei DNA vaccine encoding PbCSP
    26. P. berghei MSP1 Protein Vaccine
    27. P. berghei p36p mutant vaccine
    28. P. chabaudi AMA1 Protein Vaccine
    29. P. falciparum CS expressed in irradiated P. berghei as Vaccine
    30. P. falciparum DNA and MVA encoding ME-TRAP
    31. P. falciparum DNA Vaccine encoding EBA-175
    32. P. falciparum Hsp90 Protein Subunit Vaccine
    33. P. falciparum LSA-3 Protein Vaccine
    34. P. falciparum MSA-2 subunit vaccine
    35. P. falciparum MSP1 from transgenic mice with Freund's adjuvant
    36. P. falciparum MSP3 Protein Subunit Vaccine
    37. P. falciparum MSP4 with AFCo1 Adjuvant
    38. P. falciparum pfCelTos protein vaccine
    39. P. falciparum Pfen Protein Subunit Vaccine
    40. P. falciparum recombinant vector vaccine MVA.ME-TRAP
    41. P. falciparum Subunit SE36 Protein Vaccine
    42. P. falciparum vaccine Combination B
    43. P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
    44. P. vivax PVS25 with Montanide ISA-720
    45. P. yoelii DNA vaccine encoding MSP1
    46. P. yoelii DNA vaccine encoding PyHEP17 Protein
    47. P. yoelii DNA vaccine encoding PySSP2
    48. P. yoelii DNA vaccine pDIP/PyCSP. 1
    49. P. yoelii DNA vaccine pPyHsp60-VR1012
    50. P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine
    51. P. yoelii p36/p52 mutant vaccine
    52. P. yoelii TyCS-VLP Vaccine
    53. P. yoelii UIS3 mutant vaccine
    54. p52(-)/p36(-) GAP
    55. Pb(PfCS@UIS4)
    56. PbVac P. Berghei Whole-Sporozoite Vaccine
    57. PfAMA1-FVO/ Alhydrogel
    58. PfP0 P-BSA
    59. PfRH5 DNA Vaccine
    60. PfRipr5/ Alhydrogel
    61. PfRipr5/ CAF01
    62. PfRipr5/GLA-SE
    63. Pfs230D1-EPA/ AS01
    64. Pfs230D1-EPA/Matrix-M
    65. Pfs25 VLP-FhCMB
    66. Pfs25-EPA / AS01
    67. Pfs25-EPA/Alhydrogel
    68. Pfs25-IMX313/Matrix-M
    69. Pfs25/ Montanide ISA 51
    70. Pfs48/45 in Matrix-M
    71. PfSPZ
    72. Plasmodium FabB/FabF mutant vaccine
    73. PvCS/Montanide ISA-51
    74. PvDBPII/Matrix-M1
    75. PvRII/ AS02A
    76. PvRII/ Montanide ISA 720
    77. PvRII/​ Alhydrogel
    78. Pvs25 mRNA–LNP
    79. Pvs25-IMX313/Matrix-M1
    80. rBCGMSP1-15
    81. Recombinant ABRA protein vaccine
    82. RTS,S/AS01
    83. RTS,S/AS01E
    84. RTS,S/AS02A
    85. SAd-ME.TRAP
    86. UK39
    87. VAR2CSA
  4. References
I. General Information
1. NCBI Taxonomy ID:
5820
2. Disease:
Malaria
3. Introduction
Malaria is a vector-borne infectious disease that is widespread in tropical and subtropical regions, causing disease in approximately 400 million people and killing 1-3 million, most of them young children in Sub-Saharan Africa. It is one of the most common infectious diseases, caused by protozoan parasites of the genus Plasmodium. The most serious forms of the disease are caused by P. falciparum and P. vivax, but other related species (P. ovale, P. malariae, and sometimes P. knowlesi) can also infect humans. This group of human-pathogenic Plasmodium spp. is usually referred to as malaria parasites and are transmitted by female Anopheles mosquitoes. The parasites multiply within red blood cells, causing symptoms of anemia, as well as other general symptoms such as fever, chills, nausea, flu-like illness, and in severe cases, coma and death. No vaccine is currently available for malaria; preventative drugs must be taken continuously to reduce the risk of infection. These prophylactic drug treatments are often too expensive for most people living in endemic areas. Most adults from endemic areas have a degree of long-term recurrent infection and also of partial resistance, which reduces with time and such adults may become susceptible to severe malaria if they have spent a significant amount of time in non-endemic areas (Joy et al., 2003; Escalante et al., 1998; Kaufman et al., 2005; Meis et al., 1983).
4. Microbial Pathogenesis
Malaria in humans develops via exoerythrocytic (hepatic) and erythrocytic phases. When an infected mosquito pierces a person's skin to take a blood meal, sporozoites in the mosquito's saliva enter the bloodstream and migrate to the liver. Within 30 minutes of being introduced into the human host, they infect hepatocytes, multiplying asexually and asymptomatically for a period of 6–15 d. During this "dormant" time in the liver, the sporozoites are often referred to as "hypnozoites". Once in the liver, these organisms differentiate to yield thousands of merozoites which, following rupture of their host cells, escape into the blood and infect red blood cells, thus beginning the erythrocytic stage of the life cycle. The parasite escapes from the liver undetected by wrapping itself in the cell membrane of the infected host liver cell. Within the erythrocytes, the parasites multiply further, periodically breaking out of their hosts to invade fresh erythrocytes. Several such amplification cycles occur, resulting in the classical waves of fever. Some merozoites turn into male and female gametocytes. If a mosquito pierces the skin of an infected person, it potentially picks up gametocytes within the blood. Fertilization and sexual recombination of the parasite occurs in the mosquito's gut, thereby defining the mosquito as the definitive host of the disease. New sporozoites develop and travel to the mosquito's salivary gland, completing the cycle. Pregnant women are especially attractive to the mosquitoes, and malaria in pregnant women is an important cause of stillbirths, infant mortality and low birth weight (Talman et al., 2004; Bledsoe, 2005; Sturm et al., 2006).
5. Host Ranges and Animal Models
The vast majority of malaria cases occur in children under the age of 5 years; pregnant women are also especially vulnerable. Despite efforts to reduce transmission and increase treatment, there has been little change in which areas are at risk of this disease since 1992. Precise statistics are unknown, as the majority of cases are undocumented. Although HIV/malaria co-infection produces less severe symptoms than the interaction between HIV and TB, HIV and malaria do contribute to each other's spread. This effect comes from malaria increasing viral load and HIV infection increasing a person's susceptibility to malaria infection. Malaria is presently endemic in a broad band around the equator, in areas of the Americas, many parts of Asia, and much of Africa; however, it is in sub-Saharan Africa where 85– 90% of malaria fatalities occur. The geographic distribution of malaria within large regions is complex, and malarial and malaria-free areas are often found close to each other. In drier areas, outbreaks of malaria can be predicted with reasonable accuracy by mapping rainfall (Breman, 2001; Greenwood et al., 2005; Hay et al., 2004).
6. Host Protective Immunity
Plasmodia are relatively protected from attack by the body's immune system because for most of its life cycle it resides within liver and blood cells and is relatively invisible to immune surveillance. However, circulating infected blood cells are destroyed in the spleen. To avoid this fate, P. falciparum displays adhesive proteins on the surface of the infected blood cells, causing blood cells to stick to the walls of small blood vessels, thereby sequestering the parasite from passage through the general circulation and the spleen and giving rise to hemorrhagic complications. Endothelial venules can be blocked by the attachment of masses of these infected red blood cells (RBCs). The blockage of these vessels causes placental and cerebral malaria. Although the RBC surface adhesive proteins (called PfEMP1, for Plasmodium falciparum erythrocyte membrane protein 1) are exposed to the immune system, they do not serve as good immune targets because of their extreme diversity; there are at least 60 variations of the protein within a single parasite and perhaps limitless versions within parasite populations (Chen et al., 2000; Adams et al., 2002).
Loading...
Loading Pathogen Genes...
Loading...
Loading Host Genes...
Loading...
Loading Vaccines...
Loading References...